Trade Evotec SE - EVT CFD

Trading Conditions

• Type: CFD
• Spread: 0.030
• Long position overnight funding adjustment: -0.01661%
• Short position overnight funding adjustment: -0.00561%
• Overnight funding adjustment time: 22:00 (UTC)
• Currency: EUR
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: Germany
• Commission on trade: 0%
• Guaranteed stop premium: 1%

Key Stats

• Prev. Close: 5.4
• Open: 5.48
• 1-Year Change: -23.3%
• Day's Range: 5.305 - 5.505

About Evotec SE

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Evotec SE revenues increased 20% to EUR431M. Net income increased from EUR5.8M to EUR247M. Revenues reflect EVT Execute segment increase of 22% to EUR329M, EVT Innovate segment increase of 36% to EUR101.9M, United States segment increase of 32% to EUR142.9M, Others segment increase of 30% to EUR47.5M, United Kingdom segment increase of 8% to EUR47.2M.